Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and br… Read more
Tatva Chintan Pharma Chem Limited (TATVA) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.53 Billion INR
Based on the latest financial reports, Tatva Chintan Pharma Chem Limited (TATVA) has total liabilities worth ₹1.53 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tatva Chintan Pharma Chem Limited - Total Liabilities Trend (2018–2025)
This chart illustrates how Tatva Chintan Pharma Chem Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tatva Chintan Pharma Chem Limited Competitors by Total Liabilities
The table below lists competitors of Tatva Chintan Pharma Chem Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OPTGF
PINK:OPTGF
|
USA | $148.72 Billion |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
Indonesia | Rp48.28 Million |
|
Keding Enterprises Co Ltd
TW:6655
|
Taiwan | NT$6.22 Billion |
|
Everybot Inc.
KQ:270660
|
Korea | ₩54.10 Billion |
|
Envela Corp
NYSE MKT:ELA
|
USA | $29.87 Million |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
USA | $311.25K |
|
Indo Borax & Chemicals Limited
NSE:INDOBORAX
|
India | ₹229.98 Million |
|
DMS Co.Ltd
KQ:068790
|
Korea | ₩135.93 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Tatva Chintan Pharma Chem Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tatva Chintan Pharma Chem Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tatva Chintan Pharma Chem Limited (2018–2025)
The table below shows the annual total liabilities of Tatva Chintan Pharma Chem Limited from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹974.25 Million | +19.34% |
| 2024-03-31 | ₹816.36 Million | -66.20% |
| 2023-03-31 | ₹2.42 Billion | +30.40% |
| 2022-03-31 | ₹1.85 Billion | +24.44% |
| 2021-03-31 | ₹1.49 Billion | +13.41% |
| 2020-03-31 | ₹1.31 Billion | +21.74% |
| 2019-03-31 | ₹1.08 Billion | +26.46% |
| 2018-03-31 | ₹852.48 Million | -- |